First Commercial Distributor Readies Bavarian Nordic’s U.S. FDA-approved Mpox Vaccine

Morris & Dickson today announced it became the first U.S. commercial distributor of the JYNNEOS® vaccine. This second-generation vaccine is U.S. FDA-approved to prevent mpox and smallpox disease.

On April 3, 2024, Morris & Dickson confirmed receiving the first U.S. shipment of JYNNEOS vaccines.

This vaccine must be safely stored at minus 20 degrees Celsius. Morris & Dickson's state-of-the-art distribution techniques feature this storage and transport capability.

"We are proud to be a key partner in expanding access to this first-to-market vaccine," says Layne Martin, CEO of Head of Specialty at Morris & Dickson, in a press release. 

"JYNNEOS meets a critical public health need and helps ensure equitable access to healthcare, which in turn helps significantly prevent the spread of mpox to at-risk populations."

As of April 2024, U.S. healthcare providers in the U.S. can order JYNNEOS to make it available for at-risk individuals at local pharmacies and physician offices in addition to public health clinics.

In 2023, the U.S. CDC confirmed that the effectiveness of the JYNNEOS vaccine against mpox ranges from 36% to 75% after one dose and 66% to 89% for two doses. As of 2024, third-dose boosters have not been clinically approved.

Founded in 1841, Morris & Dickson is now approaching $6 billion in annual sales, making it the industry's largest independently owned full-line distributor. Independent pharmacies in the U.S. rely on Morris & Dickson for quick responses and straightforward business practices.

Since the global mpox outbreak began in early May 2022, more than 32,000 cases have been reported in the U.S., representing a third of all cases reported worldwide.

Bavarian Nordic's JYNNEOS (MVA-BN®, IMVAMUNE®) vaccine is available in various countries.